152 related articles for article (PubMed ID: 28052688)
1. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.
Wang X; Lopez-Beltran A; Osunkoya AO; Wang M; Zhang S; Davidson DD; Emerson RE; Williamson SR; Tan PH; Kaimakliotis HZ; Baldridge LA; MacLennan GT; Montironi R; Cheng L
Future Oncol; 2017 Apr; 13(8):705-714. PubMed ID: 28052688
[TBL] [Abstract][Full Text] [Related]
2. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
3. PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates.
Taylor AS; McKenney JK; Osunkoya AO; Chan MP; Al-Ahmadie HA; Spratt DE; Fullen DR; Chinnaiyan AM; Brown NA; Mehra R
Mod Pathol; 2020 Jun; 33(6):1165-1171. PubMed ID: 31932679
[TBL] [Abstract][Full Text] [Related]
4. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
[TBL] [Abstract][Full Text] [Related]
5. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.
Wang X; MacLennan GT; Zhang S; Montironi R; Lopez-Beltran A; Tan PH; Foster S; Baldridge LA; Cheng L
Hum Pathol; 2009 Feb; 40(2):211-7. PubMed ID: 18799188
[TBL] [Abstract][Full Text] [Related]
6. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
7. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma.
Chang A; Brimo F; Montgomery EA; Epstein JI
Hum Pathol; 2013 Aug; 44(8):1563-8. PubMed ID: 23453625
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
[TBL] [Abstract][Full Text] [Related]
9. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
[TBL] [Abstract][Full Text] [Related]
11. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
[TBL] [Abstract][Full Text] [Related]
12. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract.
Ohtsuka Y; Kawakami S; Fujii Y; Koga F; Saito K; Ando N; Takizawa T; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1322-6. PubMed ID: 16686732
[TBL] [Abstract][Full Text] [Related]
13. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
[TBL] [Abstract][Full Text] [Related]
15. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
[TBL] [Abstract][Full Text] [Related]
16. Expression status of GATA3 and mismatch repair proteins in upper tract urothelial carcinoma.
Wang Y; Zhang J; Wang Y; Wang S; Zhang Y; Miao Q; Gao F; He H
Front Med; 2019 Dec; 13(6):730-740. PubMed ID: 31020542
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.
Zhong M; Tian W; Zhuge J; Zheng X; Huang T; Cai D; Zhang D; Yang XJ; Argani P; Fallon JT; Epstein JI
Am J Surg Pathol; 2015 Jan; 39(1):127-31. PubMed ID: 25118812
[TBL] [Abstract][Full Text] [Related]
18. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]